Iranian Journal of Blood and Cancer
Iranian Journal of Blood and Cancer
Medical Sciences
http://ijbc.ir
1
admin
2008-4595
2008-4609
8
10.61186/ijbc
14
2008-4595
13
en
jalali
1401
3
1
gregorian
2022
6
1
14
2
online
1
fulltext
en
CAR-NK Cells: A Systematic Review of Emerging Alternative on Immunotherapy Against Leukemia
Pediatric Hematology & Oncology
Pediatric Hematology & Oncology
مقاله مروری
Review Article
<p style="line-height: 1.8; margin-top: 16px; margin-bottom: 16px; text-align: justify;"><span style="line-height:2;"><span style="font-size:14px;"><span style="font-family:Arial;"><strong>Background:</strong> Cancer is a public health emergency. It has a high mortality rate despite numerous studies on pharmaceutical therapies. Chimeric antigen receptor-natural killer (CAR-NK) cells are promising immunotherapy that could be used to treat cancer, especially leukemia. However, the evidence is still unclear. Thus, this systematic review aims to summarize the evidence regarding the use of CAR-NK cells as a therapy for leukemia.<br>
<strong>Method:</strong> This systematic review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement guidelines. The literature search was done using PubMed, ProQuest, ScienceDirect, and EBSCOHost with “chimeric antigen receptor”, “natural killer cell”, and “leukemia” as the primary keywords until 20 March 2020. Data collection and extraction were done by three independent reviewers. Extending a risk-of-bias approach to address in-vitro studies for assessing the risk of bias was utilized in the quality assessment of the studies.<br>
<strong>Results:</strong> The search strategy identified 221 studies. Three relevant articles met our inclusion criteria. All the included studies had a low risk of bias. The main findings from available data were as follows: (a) cytotoxicities of CAR-NK cells were found highest in cell lines expressing antigen for CAR (CD19+ cancer cells) (b) CAR-NK cells had low cytotoxicities against cells that didn’t express antigen for CAR (e.g. SR-91); (c) all studies did not result in aberrant growth of the transduced CAR-NK cells.<br>
<strong>Conclusion:</strong> The use of CAR-NK cells showed promising results in treating leukemia based on its cytotoxicity against CD19+ cancer cell lines.</span></span></span></p>
Chimeric Antigen Receptors, leukemia, natural Killer Cells, cancer, systematic Review
85
91
http://ijbc.ir/browse.php?a_code=A-10-669-1&slc_lang=en&sid=1
Alver
Prasetya
prasetyaalver@gmail.com
10031947532846008967
10031947532846008967
Yes
School of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia
Robby
Soetedjo
robbysutejo23@gmail.com
10031947532846008968
10031947532846008968
No
School of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia
Erlangga
Saputra Arifin
arifinerlangga@gmail.com
10031947532846008969
10031947532846008969
No
School of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia